Completion of 100th pAVEway Program
2017-06-20
FUJIFILM Diosynth Biotechnologies, a leading global biologics Contract Development and Manufacturing Organization (CDMO), has announced the successful completion of its 100th program using its pAVEway™ Advanced Protein Expression system which was introduced to the market during the BIO 2007 convention in Boston, Massachusetts.
pAVEway™ was developed by FUJIFILM Diosynth Biotechnologies to enable the reliable and scalable GMP manufacturing of E. coli -based processes. “As a CDMO we established ourselves early on as a leader in microbial process development and manufacturing,” said Andy Topping, Chief Scientific Officer, FUJIFILM Diosynth Biotechnologies. “Completing 100 programs and seeing many of them successfully transferred from the lab into cGMP manufacturing and subsequently to the clinic is fulfilling to everyone at Fujifilm.”